Flávia Melo Cunha de Pinho Pessoa

Ms. Flávia Melo Cunha de Pinho Pessoa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAna Beatriz Aguiar Sanford
Ana Beatriz Aguiar Sanford
LCLeidivan Sousa da Cunha
Leidivan Sousa da Cunha
CMCaio Bezerra Machado
Caio Bezerra Machado
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
ASAbigail Nayara dos Santos Silva
Abigail Nayara dos Santos Silva
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
The circadian clock (CC) is a daily system that regulates the oscillations of physiological processes and can respond to the external environment in order to maintain internal homeostasis. For the functioning of the CC, the clock genes (CG) act in different metabolic pathways through the clock-controlled genes (CCG), providing cellular regulation. The CC’s interruption can result in the development of different diseases, such as neurodegenerative and metabolic disorders, as well as cancer. Leukemias correspond to a group of malignancies of the blood and bone marrow that occur when alterations in normal cellular regulatory processes cause the uncontrolled proliferation of hematopoietic stem cells. This review aimed to associate a deregulated CC with the manifestation of leukemia, looking for possible pathways involving CG and their possible role as leukemic biomarkers.

5 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
CMCaio Bezerra Machado
Caio Bezerra Machado
IBIgor Valentim Barreto
Igor Valentim Barreto
GSGiulia Freire Sampaio
Giulia Freire Sampaio
DODeivide de Sousa Oliveira
Deivide de Sousa Oliveira
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem cells and hematopoietic progenitors, leading to the development of AML, which has a prevalence of 80% of acute leukemias in the adult population. Recurrent cytogenetic abnormalities, in addition to mediating leukemogenesis onset, participate in its evolution and can be used as established diagnostic and prognostic markers. Most of these mutations confer resistance to the traditionally used treatments and, therefore, the aberrant protein products are also considered therapeutic targets. The surface antigens of a cell are characterized through immunophenotyping, which has the ability to identify and differentiate the degrees of maturation and the lineage of the target cell, whether benign or malignant. With this, we seek to establish a relationship according to the molecular aberrations and immunophenotypic alterations that cells with AML present.

24 June 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
IBIgor Valentim Barreto
Igor Valentim Barreto
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
CMCaio Bezerra Machado
Caio Bezerra Machado
LPLaudreísa da Costa Pantoja
Laudreísa da Costa Pantoja
RRRodrigo Monteiro Ribeiro
Rodrigo Monteiro Ribeiro
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Hematopoietic stem cells (HSCs) are known for their ability to proliferate and self-renew, thus being responsible for sustaining the hematopoietic system and residing in the bone marrow (BM). Leukemic stem cells (LSCs) are recognized by their stemness features such as drug resistance, self-renewal, and undifferentiated state. LSCs are also present in BM, being found in only 0.1%, approximately. This makes their identification and even their differentiation difficult since, despite the mutations, they are cells that still have many similarities with HSCs. Although the common characteristics, LSCs are heterogeneous cells and have different phenotypic characteristics, genetic mutations, and metabolic alterations. This whole set of alterations enables the cell to initiate the process of carcinogenesis, in addition to conferring drug resistance and providing relapses. The study of LSCs has been evolving and its application can help patients, where through its count as a biomarker, it can indicate a prognostic factor and reveal treatment results. The selection of a target to LSC therapy is fundamental. Ideally, the target chosen should be highly expressed by LSCs, highly selective, absence of expression on other cells, in particular HSC, and preferentially expressed by high numbers of patients. In view of the large number of similarities between LSCs and HSCs, it is not surprising that current treatment approaches are limited. In this mini review we seek to describe the immunophenotypic characteristics and mechanisms of resistance presented by LSCs, also approaching possible alternatives for the treatment of patients.

Verified
Journal Article
Open access
PDF file
CMCaio Bezerra Machado
Caio Bezerra Machado
LCLeidivan Sousa da Cunha
Leidivan Sousa da Cunha
JMJersey Heitor Maués
Jersey Heitor Maués
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
MOMarcelo Braga de Oliveira
Marcelo Braga de Oliveira
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Human T cell leukemia virus type 1 (HTLV-1) was identified as the first pathogenic human retrovirus and is estimated to infect 5 to 10 million individuals worldwide. Unlike other retroviruses, there is no effective therapy to prevent the onset of the most alarming diseases caused by HTLV-1, and the more severe cases manifest as the malignant phenotype of adult T cell leukemia (ATL). MicroRNA (miRNA) dysfunction is a common feature of leukemogenesis, and it is no different in ATL cases. Therefore, we sought to analyze studies that reported deregulated miRNA expression in HTLV-1 infected cells and patients’ samples to understand how this deregulation could induce malignancy. Through in silico analysis, we identified 12 miRNAs that stood out in the prediction of targets, and we performed functional annotation of the genes linked to these 12 miRNAs that appeared to have a major biological interaction. A total of 90 genes were enriched in 14 KEGG pathways with significant values, including TP53, WNT, MAPK, TGF-β, and Ras signaling pathways. These miRNAs and gene interactions are discussed in further detail for elucidation of how they may act as probable drivers for ATL onset, and while our data provide solid starting points for comprehension of miRNAs’ roles in HTLV-1 infection, continuous effort in oncologic research is still needed to improve our understanding of HTLV-1 induced leukemia.

Verified
Journal Article
Open access
PDF file
RGRenan Brito Gadelha
Renan Brito Gadelha
CMCaio Bezerra Machado
Caio Bezerra Machado
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
LPLaudreísa da Costa Pantoja
Laudreísa da Costa Pantoja
IBIgor Valentim Barreto
Igor Valentim Barreto
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
The WD repeat containing antisense to TP53 (WRAP53) gene codifies an antisense transcript for tumor protein p53 (TP53), stabilization (WRAP53α), and a functional protein (WRAP53β, WDR79, or TCAB1). The WRAP53β protein functions as a scaffolding protein that is important for telomerase localization, telomere assembly, Cajal body integrity, and DNA double-strand break repair. WRAP53β is one of many proteins known for containing WD40 domains, which are responsible for mediating a variety of cell interactions. Currently, WRAP53 overexpression is considered a biomarker for a diverse subset of cancer types, and in this study, we describe what is known about WRAP53β’s multiple interactions in cell protein trafficking, Cajal body formation, and DNA double-strand break repair and its current perspectives as a biomarker for cancer.

24 January 2024 in Genes
Verified
Journal Article
Open access
PDF file
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
VVVitória Beatriz de Jesus Viana
Vitória Beatriz de Jesus Viana
MOMarcelo Braga de Oliveira
Marcelo Braga de Oliveira
BNBeatriz Maria Dias Nogueira
Beatriz Maria Dias Nogueira
RRRodrigo Monteiro Ribeiro
Rodrigo Monteiro Ribeiro
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Reference genes are used as internal reaction controls for gene expression analysis, and for this reason, they are considered reliable and must meet several important criteria. In view of the absence of studies regarding the best reference gene for the analysis of acute leukemia patients, a panel of genes commonly used as endogenous controls was selected from the literature for stability analysis: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Abelson murine leukemia viral oncogene human homolog 1 (ABL), Hypoxanthine phosphoribosyl-transferase 1 (HPRT1), Ribosomal protein lateral stalk subunit P0 (RPLP0), β-actin (ACTB) and TATA box binding protein (TBP). The stability of candidate reference genes was analyzed according to three statistical methods of assessment, namely, NormFinder, GeNorm and R software (version 4.0.3). From this study’s analysis, it was possible to identify that the endogenous set composed of ACTB, ABL, TBP and RPLP0 demonstrated good performances and stable expressions between the analyzed groups. In addition to that, the GAPDH and HPRT genes could not be classified as good reference genes, considering that they presented a high standard deviation and great variability between groups, indicating low stability. Given these findings, this study suggests the main endogenous gene set for use as a control/reference for the gene expression in peripheral blood and bone marrow samples from patients with acute leukemias is composed of the ACTB, ABL, TBP and RPLP0 genes. Researchers may choose two to three of these housekeeping genes to perform data normalization.